Zymeworks says Phase 1 data show ZW191 ADC posts 78.6% response rate in FRα-positive platinum-resistant ovarian cancer patients

Zymeworks Inc.

Zymeworks Inc.

ZYME

0.00
  • Zymeworks presented new Phase 1 dose-escalation data for FRα-targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026.
  • Study readout showed tumor shrinkage in platinum-resistant ovarian cancer, including patients with low or negative FRα expression.
  • Responses appeared durable at the data cutoff, supporting continued development and potential differentiation versus FRα-targeted competitors.
  • Dose-optimization enrollment in about 60 ovarian cancer patients is complete; results will be presented at a future medical meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141805OMX_____CNEWS_EN_GNW9746126_en) on June 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.